metricas
covid
Buscar en
Gastroenterología y Hepatología
Toda la web
Inicio Gastroenterología y Hepatología Factores que influyen en la decisión de administrar corticoides sistémicos en ...
Información de la revista
Vol. 27. Núm. 8.
Páginas 444-449 (enero 2004)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 27. Núm. 8.
Páginas 444-449 (enero 2004)
Acceso a texto completo
Factores que influyen en la decisión de administrar corticoides sistémicos en la enfermedad de Crohn
Factors influencing the decision to administer systemic corticosteroids in crohn's disease
Visitas
3650
P. Nos
Autor para correspondencia
pnosm@meditex.es

Correspondencia: Dra. P. Nos. Servicio de Medicina Digestiva. Hospital La Fe. Avda. Campanar, 21. 46009 Valencia. España.
, G. Bastida, V. Garrigues, F. Calvo, M. Ponce, N. Maroto, J. Ponce
Servicio de Medicina Digestiva. Hospital La Fe. Valencia. España
Este artículo ha recibido
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas
Introducción

La enfermedad de Crohn cursa con períodos de exacerbación y remisión. Los corticoides han sido los fármacos más utilizados en los brotes de actividad. El objetivo de este estudio es conocer qué parámetros clínicos y analíticos se asocian con la decisión terapéutica de administrar corticoides en el curso de la enfermedad.

Material y método

Se seleccionaron de una base de datos 207 visitas consecutivas realizadas en 62 pacientes con enfermedad de Crohn y se compararon los datos de las visitas en las que se había iniciado la administración de corticoides (n = 65) con los de aquellas en las que tal decisión no se tomó (n = 142). Se realizó un análisis univariante y multivariante (regresión logística). Los resultados se expresan como odds ratio (OR) con el intervalo de confianza (IC) del 95%.

Resultados

En el análisis univariante se detectaron diferencias estadísticamente significativas entre los grupos en cuanto a la localización, el tratamiento de mantenimiento, el valor del Crohn's Disease Activity Index (CDAI), la presencia de dolor abdominal, masa, enfermedad perianal, las manifestaciones extraintestinales y todos los parámetros analíticos (leucocitos, plaquetas, fibrinógeno, velocidad de sedimentación globular y proteína C reactiva). En el análisis multivariante (administración de corticoides como variable dependiente) se detectó una asociación positiva, estadísticamente significativa, entre la decisión de administrar corticoides y el CDAI leve (OR = 31,9; IC del 95%, 6,6-154,1), moderado o grave (OR = 49,7; IC del 95%, 6,1-401,3), la localización ileocólica (OR = 4,8; IC del 95%, 1-22,1) y la presencia de enfermedad perianal (OR = 7,4; IC del 95%, 1,5-35,9), y una asociación negativa con el tratamiento de mantenimiento con inmunosupresores (OR = 0,05; IC del 95%, 0,30-0,008). Las variables de laboratorio asociadas positivamente con la administración de corticoides fueron la proteína C reactiva y la cifra de leucocitos.

Conclusión

El valor del CDAI es la variable de mayor valor predictivo para la prescripción de corticoides, aunque otras variables clínicas y analíticas no incluidas en este índice también se asocian con esta decisión terapéutica. Existe una asociación negativa entre el uso de inmunosupresores y la prescripción de corticoides.

Introduction

Crohn's disease shows periods of exacerbation and remission. Corticosteroids are the most frequently used drugs in exacerbations of disease activity. The objective of this study is to determine which clinical and laboratory parameters are associated with the therapeutic decision to administer corticosteroids during the course of the disease.

Material and method

Two-hundred seven consecutive visits made by 62 patients with Crohn's disease were selected from a database. Data from visits in which corticosteroid administration was initiated (n = 65) were compared with those from visits in which this decision was not made (n = 142). Univariate and multivariate (logistic regression) analyses were performed. The results are expressed as odds ratio (OR) with 95% confidence interval (95% CI).

Results

In the univariate analysis statistically significant differences were found between groups in localization, maintenance treatment, Crohn's Disease Activity Index (CDAI) score, the presence of abdominal pain, mass, perianal disease, extraintestinal manifestations and all laboratory parameters (leukocytes, platelets, fibrinogen, erythrocyte sedimentation rate, C-reactive protein). In the multivariate analysis (with corticosteroid administration as the dependent variable) a statistically significant positive association was found between the decision to administer corticosteroids and mild (OR = 31.9; 95% CI, 6.6-154.1), moderate or severe (OR = 49.7; 95% CI, 6.1-401.3) CDAI, ileocolic localization (OR = 4.8; 95% CI, 1-22.1) and the presence of peria-nal disease (OR = 7.4; 95% CI, 1.5-35.9), while a negative association was found with maintenance treatment with immunosuppressant drugs (OR = 0.05; 95% CI, 0.30-0.008). The laboratory variables positively associated with corticosteroid administration were C-reactive protein and leukocyte count.

Conclusion

The variable with greatest predictive value for corticosteroid prescription is the CDAI score, although other clinical and laboratory variables not included in this index are also associated with corticosteroid administration. There is a negative association between the use of immunosuppressive drugs and corticosteroid prescription.

El Texto completo está disponible en PDF
Bibliografía
[1.]
W.R. Best, J.M. Becktel, J.W. Singleton, F. Kern Jr..
Development of a Crohn's disease activity index.
Gastroenterology, 70 (1976), pp. 439-444
[2.]
P. Nos, J. Clofent.
Enfermedad de Crohn.
Tratamiento de las enfermedades gastroenterológicas,
[3.]
S.B. Hanauer, W. Sandborn.
The Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn's disease in adults.
Am J Gastroenterol, 96 (2001), pp. 635-643
[4.]
O.H. Nielsen, B. Vainer, S.M. Madsen, J.B. Seidelin, NH. Heegaard.
Established and emerging biological markers of inflammatory bowel disease.
Am J Gastroenterol, 95 (2000), pp. 359-367
[5.]
JE. Lennard-Jones.
Classification of inflammatory bowel disease.
Scand J Gastroenterol Suppl, 170 (1989), pp. 2-6
[6.]
C. Gasche, J. Scholmerich, J. Brynskov, G. D'Haens, S.B. Hanauer, E.J. Irvine, et al.
A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology. Vienna 1998.
Inflamm Bowel Dis, 6 (2000), pp. 8-15
[7.]
E.V. Loftus, P. Schoenfeld, WJ. Sandborn.
The epidemiology and natural history of Crohn's disease in population-based patients cohorts from North America: a systematic review.
Aliment Pharmacol Ther, 16 (2002), pp. 51-60
[8.]
PJ. Rutgeerts.
Conventional treatment of Crohn's disease: objectives and outcomes.
Inflamm Bowel Dis, 7 (2001), pp. 2-8
[9.]
P. Munkholm, E. Langholz, M. Davidsen, V. Binder.
Frequency of glucocorticoid resistance and dependency in Crohn's disease.
Gut, 35 (1994), pp. 360-362
[10.]
W.A. Faubion, E.V. Loftus, W.S. Harmsen, A.R. Zinsmeister, WJ. Sandborn.
The natural history of corticosteroid therapy for inflammatory bowel disease.
Gastroenterology, 121 (2001), pp. 255-260
[11.]
P. Munkholm, E. Langholz, M. Davidsen, V. Binder.
Disease activity courses in a regional cohort of Crohn's disease patients.
Scand J Gastroenterol, 30 (1995), pp. 699-706
[12.]
M.D. Silverstein, E.V. Loftus, W.J. Sandborn, W.J. Tremaine, B.G. Feagan, P.J. Nietert, et al.
Clinical course and cost of care for Crohn's disease: Markov model analysis of a population-based cohort.
Gastroenterology, 117 (1999), pp. 49-57
[13.]
W.J. Sandborn, B.G. Feagan, S.B. Hanauer, H. Lochs, R. Lofberg, R. Modigliani, et al.
A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease.
Gastroenterology, 122 (2002), pp. 512-530
[14.]
S.R. Targan, S.B. Hanauer, S.J. Van Deventer, L. Mayer, D.H. Present, T. Braakman, et al.
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
N Engl J Med, 337 (1997), pp. 1029-1035
[15.]
W.J. Sandborn, B.G. Feagan, S.B. Hanauer, D.H. Present, L.R. Sutherland, M.A. Kamm, et al.
An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial.
Gastroenterology, 120 (2001), pp. 1330-1338
[16.]
W.J. Sandborn, S.B. Hanauer, S. Katz, M. Safdi, D.G. Wolf, R.D. Baerg, et al.
Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.
Gastroenterology, 121 (2001), pp. 1088-1094
[17.]
R.N. Fedorak, A. Gangl, C.O. Elson, P. Rutgeerts, S. Schreiber, G. Wild, et al.
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group.
Gastroenterology, 119 (2000), pp. 1473-1482
[18.]
S. Schreiber, R.N. Fedorak, O.H. Nielsen, G. Wild, C.N. Williams, S. Nikolaus, et al.
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group.
Gastroenterology, 119 (2000), pp. 1461-1472
[19.]
JW. Singleton.
The Crohn's Disease Activity Index is a useful tool in clinical practice of gastroenterology.
Inflamm Bowel Dis, 5 (1999), pp. 138
[20.]
BI. Korelitz.
Is the Crohn's Disease Activity Index outdated? Yes. Is it the gold standard that clinicians should use? No.
Inflamm Bowel Dis, 5 (1999), pp. 139-140
[21.]
EJ. Irvine.
McMaster IBD Study Group. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index.
J Clin Gastroenterol, 20 (1995), pp. 27-32
[22.]
D.H. Present, P. Rutgeerts, S. Targan, S.B. Hanauer, L. Mayer, R.A. Van Hogezand, et al.
Infliximab for the treatment of fistulas in patients with Crohn's disease.
N Engl J Med, 340 (1999), pp. 1398-1405
[23.]
GR. Linchtenstein.
Treatment of fistulizing Crohn disease.
Gastroenterology, 119 (2000), pp. 1132-1147
[24.]
J.P. Gisbert, F. Gomollón, J. Maté, J.M. Figueroa, R. Alós, JM. Pajares.
Tratamiento de la enfermedad de Crohn estenosante.
Gastroenterol Hepatol, 9 (2002), pp. 411-416
[25.]
J.B. Felder, D.J. Adler, BI. Korelitz.
The safety of corticosteroid therapy in Crohn's disease with an abdominal mass.
Am J Gastroenterol, 86 (1991), pp. 1450-1455
[26.]
W. Sandborn, L. Sutherland, D. Pearson, G. May, R. Modigliani, C. Prantera.
Azathioprine or 6-mercaptopurine for induccing remission of Crohn's disease (Cochrane Review). En: The Cochrane Library. Issue 2.
[27.]
D.C. Pearson, G.R. May, G.H. Fick, LR. Sutherland.
Azathioprine for maintaining remission of Crohn disease (Cochrane Review). En: The Cochrane Library, Issue 2.
[28.]
C. Niederau, F. Backmerhoff, B. Schumacher, C. Niederau.
Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis.
Hepatogastroenterology, 44 (1997), pp. 90-107
[29.]
E.A. Fagan, R.F. Dyck, P.N. Maton, H.J. Hodgson, V.S. Chadwick, A. Petrie, et al.
Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis.
Eur J Clin Invest, 12 (1982), pp. 351-359
[30.]
A. Moran, A. Jones, P. Asquith.
Laboratory markers of colonoscopic activity in ulcerative colitis and Crohn's colitis.
Scand J Gastroenterol, 30 (1995), pp. 356-360
Copyright © 2004. Elsevier España, S.L.. Todos los derechos reservados
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos